Table 2 Consultation and anticoagulation characteristics
DOAC (n = 158) | VKA (n = 419) | Total (n = 577) | p | |
|---|---|---|---|---|
Consultation | ||||
Referral, [n (%)] | ||||
Ambulance | 47 (29.7) | 138 (32.9) | 185 (32.1) | |
General Practitioner | 15 (9.5) | 41 (9.8) | 56 (9.7) | |
External Hospital | 32 (20.3) | 75 (17.9) | 107 (18.5) | |
Air Rescue | 0 (0.0) | 8 (1.9) | 8 (1.4) | |
Walk-In | 37 (23.4) | 72 (17.2) | 109 (18.9) | |
Internal Referral | 5 (3.2) | 10 (2.4) | 15 (2.6) | |
No Information | 22 (13.9) | 75 (17.9) | 97 (16.8) | 0.282 |
Triage, [n (%)] | ||||
Life-threatening | 29 (18.4) | 72 (17.2) | 101 (17.5) | |
Urgent conditions | 71 (44.9) | 194 (46.3) | 265 (45.9) | |
Semi-urgent conditions | 51 (32.3) | 134 (32.0) | 185 (32.1) | |
Non urgent conditions | 3 (1.9) | 8 (1.9) | 11 (1.9) | |
Missing | 4 (2.5) | 11 (2.6) | 15 (2.6) | 0.998 |
Trauma | 38 (24.1) | 138 (32.9) | 176 (30.5) | 0.039 |
Anticoagulation | ||||
Medication, [n (%)] | ||||
Phenprocoumon | 415 (99.0) | 415 (71.9) | ||
Acenocumarol | 4 (1.0) | 4 (0.7) | ||
Rivaroxaban | 141 (89.2) | 141 (24.4) | ||
Dabigatran | 6 (3.8) | 6 (1.0) | ||
Apixaban | 9 (5.7) | 9 (1.6) | ||
Edoxaban | 2 (1.3) | 2 (0.3) | < 0.001 | |
Reason OAK, [n (%)] | ||||
Mechanical valve | 2 (1.3) | 36 (8.6) | 38 (6.6) | |
Venous embolism | 34 (21.5) | 59 (14.1) | 93 (16.1) | |
Atrial fibrillation | 85 (53.8) | 202 (48.2) | 287 (49.7) | |
Combination | 17 (10.8) | 56 (13.4) | 73 (12.7) | |
Other | 5 (3.2) | 17 (4.1) | 22 (3.8) | |
Unknown | 15 (9.5) | 49 (11.7) | 64 (11.1) | 0.009 |
INR | 1.3 (1.1–1.5) | 2.4 (1.7–3.3) | 2.0 (1.3–3.0) | < 0.001 |
Antiplatelet therapy, [n (%)] | 52 (32.9) | 121 (28.9) | 173 (30.0) | 0.346 |